{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:03:32Z","timestamp":1768781012384,"version":"3.49.0"},"reference-count":26,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background. The aim of this pilot study was to evaluate the value of imaging techniques, including computed tomography (CT) and magnetic resonance imaging (MRI), in the diagnosis of a tumor-bowel fistula as a rare form of epithelial ovarian cancer (EOC) relapse. We also performed an initial assessment of the effectiveness of the treatment of this form of relapse. Methods. The study group consisted of eight patients with suspected platinum-sensitive recurrence in the form of a tumor\/bowel fistula. All patients finished their first line of chemotherapy and subsequently showed complete remission for 6 months or more. To qualify patients for further treatment, CT and MRI were performed, which suggested the presence of a fistula between the recurrent tumor and intestine. DESKTOP study criteria were used to qualify patients for secondary cytoreduction. Second-line chemotherapy was given after secondary debulking. Results. In all patients, fistulas formed between the tumor and large bowel. On CT, the fistulas were indirectly visible. In all cases, the fistula was visible on MR images, which showed hypointensity on the T2 and T1 post-contrast sequences but did not show restricted diffusion on the diffusion-weighted imaging (DWI) sequence. Patients who were qualified for the study underwent secondary debulking with bowel resection. In all eight cases, the fistula between the tumor and surrounding organs was confirmed. During surgery, seven intestinal anastomoses and one colostomy were performed. No residual macroscopic tumor remained in seven cases (resection R0-87.5%). The progression-free survival (PFS) was 8.4\u201322.6 months (median 13.4). In the group with cytoreduction R0, the median PFS was 15.5 months (12\u201322). Conclusion. In patients with suspected EOC recurrence with clinically suspected fistula, CT scan is not sufficient. In CT, the presence of a fistula is suspected based on indirect symptoms. MRI, as a method with much greater tissue resolution, confirms the diagnosis. In addition, MRI can identify the point of the tumor\/bowel junction. This is especially true with a large infiltration covering several intestinal parts. Bowel resection with simultaneous anastomosis is a good and safe solution for these patients. However, appropriate qualification for the procedure is necessary, which will allow for surgery without residual macroscopic disease (R0 surgery). Due to the small number of cases, our results cannot be generalized. We treat them as a hypothesis that can be verified in a larger study.<\/jats:p>","DOI":"10.3390\/curroncol30010040","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T05:15:53Z","timestamp":1672377353000},"page":"506-517","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor-Bowel Fistula as a Rare Form of Recurrent Ovarian Cancer\u2014Imaging and Treatment: Preliminary Report"],"prefix":"10.3390","volume":"30","author":[{"given":"Melania","family":"Jankowska-Lombarska","sequence":"first","affiliation":[{"name":"Second Department of Clinical Radiology, Medical University of Warsaw, Banacha 1a St., 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6511-6579","authenticated-orcid":false,"given":"Laretta","family":"Grabowska-Derlatka","sequence":"additional","affiliation":[{"name":"Second Department of Clinical Radiology, Medical University of Warsaw, Banacha 1a St., 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9406-6868","authenticated-orcid":false,"given":"Pawel","family":"Derlatka","sequence":"additional","affiliation":[{"name":"Second Department Obstetrics and Gynecology, Medical University of Warsaw, Karowa 2 St., 00-315 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: Esmo Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ygyno.2013.03.026","article-title":"An International Assessment of Ovarian Cancer Incidence and Mortality","volume":"130","author":"Lowe","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2017.02.023","article-title":"Optimal Primary Management of Bulky Stage Iiic Ovarian, Fallopian Tube and Peritoneal Carcinoma: Are the Only Options Complete Gross Resection at Primary Debulking Surgery or Neoadjuvant Chemotherapy?","volume":"145","author":"Sioulas","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Research European Organization for, Group Treatment of Cancer-Gynaecological Cancer, and Ncic Clinical Trials Group. Neoadjuvant Chemotherapy or Primary Surgery in Stage Iiic or Iv Ovarian Cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON 7): Overall Survival Results of a Phase 3 Randomised Trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (Ago) Desktop Ovar Trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study Desktop II. A Project of the Ago Kommission Ovar, Ago Study Group, Noggo, Ago-Austria, and Mito","volume":"21","author":"Harter","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"497429","DOI":"10.1155\/2010\/497429","article-title":"Treatment for Recurrent Ovarian Cancer-at First Relapse","volume":"2010","author":"Ushijima","year":"2010","journal-title":"J. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1447-0756.2010.01341.x","article-title":"Ovarian Carcinoma Complicated by Sigmoid Colon Fistula Formation: A Case Report and Review of the Literature","volume":"37","author":"Yahagi","year":"2011","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00261-012-9913-3","article-title":"Bevacizumab-Induced Perforation of the Gastrointestinal Tract: Clinical and Radiographic Findings in 11 Patients","volume":"38","author":"Borofsky","year":"2013","journal-title":"Abdom. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13244-019-0812-9","article-title":"Elucidating Vaginal Fistulas on Ct and Mri","volume":"10","author":"Tonolini","year":"2019","journal-title":"Insights Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1102\/1470-7330.2007.9046","article-title":"Mr Imaging in Ovarian Cancer","volume":"7","author":"Sohaib","year":"2007","journal-title":"Cancer Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00330-010-1886-4","article-title":"Esur Guidelines: Ovarian Cancer Staging and Follow-Up","volume":"20","author":"Forstner","year":"2010","journal-title":"Eur. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1148\/rg.2018170167","article-title":"Imaging and Surgical Management of Anorectal Vaginal Fistulas","volume":"38","author":"VanBuren","year":"2018","journal-title":"Radiographics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.diii.2016.11.002","article-title":"Added Value of Diffusion-Weighted Magnetic Resonance Imaging for the Diagnosis of Perianal Fistula","volume":"98","author":"Cavusoglu","year":"2017","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00261-018-1677-y","article-title":"Imaging Strategy in Recurrent Ovarian Cancer: A Practical Review","volume":"44","author":"Manganaro","year":"2019","journal-title":"Abdom. Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1148\/rg.321115040","article-title":"Mr Imaging Evaluation of Perianal Fistulas: Spectrum of Imaging Features","volume":"32","author":"Rivas","year":"2012","journal-title":"Radiographics"},{"key":"ref_20","first-page":"91","article-title":"Role of Diffusion-Weighted Imaging in the Evaluation of Perianal Fistulae","volume":"31","author":"Boruah","year":"2021","journal-title":"Indian J. Radiol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1186\/s40064-016-3426-4","article-title":"Ovarian Mature Cystic Teratoma with Fistula Formation into the Rectum: A Case Report","volume":"5","author":"Kizaki","year":"2016","journal-title":"Springerplus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clinimag.2019.03.005","article-title":"Ovarian Dermoid Cyst Complicated by Small Bowel Obstruction, Entero-Ovarian Fistula Formation, and Malignant Degeneration","volume":"56","author":"Esterson","year":"2019","journal-title":"Clin. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.3802\/jgo.2021.32.e42","article-title":"Rectosigmoid Resection During Visceral-Peritoneal Debulking (Vpd) in Patients with Stage Iiic-Iv Ovarian Cancer: Morbidity of Gynecologic Oncology Vs. Colorectal Team","volume":"32","author":"Tozzi","year":"2021","journal-title":"J. Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.3802\/jgo.2021.32.e51","article-title":"Rectosigmoid Resection by Gynecologic Oncologists Versus Colorectal Surgeons: As Long as It Catches the Mouse, Does the Color of the Cat Matter?","volume":"32","author":"Chang","year":"2021","journal-title":"J. Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2014.09.017","article-title":"Impact of Secondary Cytoreductive Surgery on Survival in Patients with Platinum Sensitive Recurrent Ovarian Cancer: Analysis of the Calypso Trial","volume":"136","author":"Lee","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Platinum-Sensitive Relapsed Ovarian Cancer (Soc-1): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/1\/40\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:55:56Z","timestamp":1760147756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/1\/40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["curroncol30010040"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30010040","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]}}}